Compare abrdn Physical Palladium Shares ETF (PALL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Physical Palladium Shares ETF vs Pfizer Inc — how do they compare? abrdn Physical Palladium Shares ETF trades at $23.33, while Pfizer Inc trades at $24.91 (market cap $142.14B). The key difference: Pfizer Inc pays a 6.9% dividend while abrdn Physical Palladium Shares ETF pays none, and Pfizer Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| PALL | PFE | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.18 | $28.56 |
52-Week Low | $19.96 | $23.29 |
Market Cap | — | $142.14B |
Volume | — | 29,869,932 |
Enterprise Value | — | $192.80B |
Dividend Yield | — | 6.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PALL trades at $22.80, up 0.44% on the day, with a bearish technical signal from moving averages. The stock recently underwent a 1:5 forward split effective May 18, 2026. Recent news highlights palladium's underperformance in the precious metals rally, with some analysts viewing current price weakness as a potential buying opportunity due to supply risks and industrial demand.
The outlook for PALL hinges on a recovery in palladium prices, with sentiment mixed. Opportunities exist if industrial demand strengthens and supply constraints materialize, but risks include continued commodity price volatility and broader economic pressures that could dampen demand.
Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.
PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
